How to Maintain Weight Loss After a Medical Program Ends
How to Maintain Weight Loss After a Medical Program Ends Reaching your weight loss goal is a real achievement. It
April 19, 2026
No Comments
If you have been researching prescription weight loss medications, you have almost certainly encountered both semaglutide and tirzepatide. They are the two most talked-about options in the GLP-1 medication category right now, and for good reason. Both have produced meaningful results in clinical trials, and both represent a genuine shift in what medically supervised weight loss can achieve.
But they are not the same medication, and understanding how they differ matters if you are trying to make an informed decision about which might be more appropriate for your situation.
This guide covers how semaglutide and tirzepatide each work, what the clinical evidence shows for each, how their side effect profiles compare, and what factors a provider considers when choosing between them.
Semaglutide is a GLP-1 receptor agonist, which means it mimics the action of glucagon-like peptide-1, a hormone your body naturally produces after eating. GLP-1 signals to the brain that you are full, slows digestion, and helps regulate blood sugar levels.
For weight management, semaglutide is available under the brand name Wegovy, which was specifically FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. Ozempic, which contains the same active ingredient, is approved specifically for type 2 diabetes but is sometimes prescribed off-label for weight loss.
Semaglutide is administered as a once-weekly subcutaneous injection. The dose is gradually increased over several months to minimize side effects and allow the body to adjust.
Tirzepatide is a newer medication that works differently from semaglutide in one important way. While semaglutide targets only the GLP-1 receptor, tirzepatide is a dual agonist that targets both the GLP-1 receptor and the GIP receptor simultaneously.
GIP stands for glucose-dependent insulinotropic polypeptide, which is another hormone involved in appetite regulation, fat metabolism, and insulin secretion. By targeting both receptors, tirzepatide engages two complementary hormonal pathways at once rather than one.
For weight management, tirzepatide is available under the brand name Zepbound, which received FDA approval for chronic weight management in 2023. Mounjaro contains the same active ingredient and is approved for type 2 diabetes.
Like semaglutide, tirzepatide is administered as a once-weekly subcutaneous injection, and the dose is gradually titrated upward over time.
The pivotal clinical trial for semaglutide’s weight management indication was the STEP 1 trial, published in The New England Journal of Medicine. In that trial, participants using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 14.9 percent of their body weight over 68 weeks, compared to 2.4 percent in the placebo group.
These results represented a significant advancement over previously available weight loss medications and established semaglutide as a leading option in medical weight management.
Tirzepatide’s weight management trials produced notably strong results. In the SURMOUNT-1 trial, published in The New England Journal of Medicine, participants using tirzepatide at the highest dose of 15 mg lost an average of approximately 20.9 percent of their body weight over 72 weeks, compared to 3.1 percent in the placebo group.
At lower doses, results were also meaningful. Participants on 5 mg tirzepatide lost an average of approximately 15 percent of body weight, and those on 10 mg lost approximately 19.5 percent.
Direct head-to-head trials comparing semaglutide and tirzepatide in a weight management population specifically are still emerging. However, the available data suggests that tirzepatide produces somewhat greater average weight loss at comparable treatment durations, likely because of its dual mechanism targeting both GLP-1 and GIP receptors.
It is important to note that average trial results represent a population, not an individual. Some people respond more strongly to semaglutide than others, and the same is true for tirzepatide. Individual response is influenced by genetics, metabolism, adherence, lifestyle factors, and other variables that cannot be fully predicted in advance.
Both semaglutide and tirzepatide share a similar side effect profile because they both activate the GLP-1 receptor. The most commonly reported side effects for both medications are gastrointestinal in nature.
Common side effects for both:
The frequency and severity of gastrointestinal side effects appear to be broadly similar between the two medications, though individual experiences vary. Both medications use a gradual dose escalation strategy specifically to minimize the intensity of these effects during the adjustment period.
Serious but rare risks that apply to both:
Both medications are contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.
One notable difference: some early reports and patient accounts suggest that tirzepatide may produce slightly less nausea than semaglutide at equivalent therapeutic doses, potentially because the GIP component has some counterbalancing effect on GLP-1-mediated gastrointestinal activity. This is not definitively established in large-scale comparative trials, but it is a pattern worth being aware of.
The honest answer is that neither medication is universally better than the other. The right choice depends on a combination of clinical, practical, and individual factors that a qualified provider is best positioned to evaluate.
Tirzepatide may be worth discussing if:
Semaglutide may be worth discussing if:
Cost and access are real practical considerations. Both medications are expensive without insurance coverage, and availability has been affected by demand and supply chain issues at various points. A direct pay telehealth provider can help you navigate current availability and pricing as part of your consultation.
If you are exploring medical weight loss options and are unsure which medication might be appropriate for your situation, a qualified provider can review your full health history, current medications, weight history, and goals to make a personalized recommendation. For men who are also experiencing symptoms of low testosterone alongside weight challenges, completing the ADAM Questionnaire for Men before your consultation can help your provider evaluate both concerns together. For patients outside of a provider’s primary service area, out-of-state telehealth consultations make this conversation accessible without requiring an in-person visit.
Regardless of which medication your provider prescribes, the experience of starting treatment follows a similar arc. Treatment begins at a low starting dose that is gradually increased over weeks to months. This titration process is intentional and important for minimizing side effects.
During the early weeks, most patients notice a reduction in appetite and some degree of gastrointestinal adjustment. Over the following weeks and months, weight loss progresses as the medication reaches its maintenance dose and the body adapts.
Regular follow-up with your provider is an essential part of treatment with either medication. Lab work, weight monitoring, and medication management are all components of responsible oversight. This is equally manageable through a telehealth provider as through an in-person clinic.
Yes, switching between medications is possible and sometimes clinically appropriate. If you have not achieved adequate results on one medication, your provider may recommend transitioning to the other. This transition should always be managed by your provider to ensure appropriate dosing during the switch.
Clinical trial data suggests tirzepatide produces greater average weight loss at maximum doses, likely due to its dual GLP-1 and GIP mechanism. However, individual response varies significantly, and stronger average results in a trial population do not guarantee greater results for any specific individual.
Yes. Qualified telehealth providers can evaluate your eligibility for either medication, order necessary lab work, and prescribe the appropriate option if you are a candidate. Learn more about out-of-state consultation options to understand how the process works.
Yes. Both semaglutide and tirzepatide are most effective when used as part of a comprehensive approach that includes dietary changes, physical activity, and behavioral support. Neither medication is a standalone solution, and the best outcomes in clinical trials consistently involved lifestyle intervention alongside medication.
Duration of treatment is an individual decision made with your provider. Research suggests that stopping either medication without a maintenance plan in place is associated with weight regain over time. Your provider can help you determine the appropriate duration and develop a long-term strategy that protects your results.
A small percentage of patients do not respond adequately to GLP-1 based medications. If this is the case, your provider can explore alternative approaches within a medical weight loss program and discuss what other options may be clinically appropriate given your individual health picture.
The comparison between semaglutide vs tirzepatide is not a question with a single right answer. Both are clinically effective, FDA-approved prescription weight loss medications with meaningful evidence behind them. Tirzepatide’s dual mechanism produces somewhat greater average weight loss in trials, while semaglutide has a longer track record and slightly broader clinical familiarity.
The most important step is not deciding between them on your own. It is working with a qualified provider who can evaluate your full clinical picture and recommend the option most likely to produce lasting results for your specific situation. If you are ready to explore your options, a medical weight loss consultation is the right place to start.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan.
How to Maintain Weight Loss After a Medical Program Ends Reaching your weight loss goal is a real achievement. It
How Long Does TRT Take to Work? A Realistic Timeline of What to Expect One of the most common questions
Testosterone Injections vs. Gel: Which Form of TRT Is Right for You? If you have been diagnosed with low testosterone
What Are GLP-1 Medications and How Do They Help With Weight Loss? If you have been paying attention to conversations
Currently only accepting new clients from: New Mexico, Utah, Minnesota, Maryland, Virginia, Delaware, Colorado, West Virginia, Arizona, Iowa, Florida, Nevada, and Connecticut.